Warning Signs for SMBs in US, don't miss this


In This Newsletter, We Will Talk About

A Quick 4 mins Insights into:

  • The Dire State of SMBs in United States
  • The Biggest Opportunity for the founders serving SMBs, in US?
  • A Free Giveaway, do you follow Innovation in health Care, then you will going to love this
Did you know that America’s 33 million small businesses stock over $800 billion in finished goods?

But this very scale is now creating, once in a decade, brink of disaster for these businesses in 2025.

In June 2025, 12% of U.S. small business owners reported their inventories were "too high", nearly double the rate from May and highest ever in last 10 years.
That’s not a rounding error; it’s billions of dollars in product gathering dust while loan payments and rent still come due.

Inventory isn’t just a warehouse metric: under GDP math, every extra pallet boosts growth on the way up and yanks it down when firms finally liquidate.

For context:

  • Previous lows: –7 % (Oct/Nov 2020 pandemic whiplash)
  • 2023‑24 range: –1 % to –5 %
Did you know that NFIB research shows a 0.6 correlation between a firm’s inventory-turn ratio and its head-count change half a year later?

Translation- Excess stock today is a statistical omen of layoffs and hiring freezes in the next two quarters.

Why should America worry about it?:

  • Demand vs. Supply Mismatch: Rising stock = customers stopped buying.
  • Cycle Multiplier: Firms cut production during gluts, stretching downturns.
  • Purchase Slump: Businesses are slow to dial back POs, so excess balloons before action.

Bottom line: Excess stock is both warning light and wrecking ball, and right now it’s flashing red across Main Street.

Life becomes Tougher for Founders selling to SMBs:

  • Cash Is Trapped in Boxes: Every unsold SKU ties up dollars that could fund marketing, R&D, or payroll.
  • Credit Lines Tighten: Lenders discount collateral value on aging stock, hiking rates exactly when you’re most desperate.
  • GDP Mirage Ahead: Current “growth” partly rests on warehouses filling. The draw‑down quarter will feel like sudden winter.
  • Opportunity for the Lean: If your balance sheet is light, you can acquire inventory, customers, or full businesses at fire‑sale valuations.

To Put things in Perspective, These many Jobs are at risk!!!!

Key Takeaway for Founders:

0–3 Months:

  • Apparel, electronics peripherals, and seasonal home goods show High risks.
  • Arrange short‑term lines so you can strike when clearance lists drop.
  • Opportunity for inventory‑financing products to overstocked peers

3–6 Months:

  • Take over purchase orders or entire brands for cents on the dollar
  • Partner to clear, refurb, or recycle stock, take margins, unclaimed by many.
  • Weekly SKU‑level forecasting via AI tools to avoid catching the same disease.

Heads up for Founders and VCs, if you are looking at these sectors:

Favourable:

  • Liquidation marketplaces & reverse‑logistics SaaS
  • Working‑capital fintechs secured by inventory
  • Re‑commerce platforms: Refurb, Resale, Recycle

At Risk:

  • Trend‑cycle fashion boutiques
  • Furniture & appliance sellers with Q4‑weighted demand
  • DTC brands lacking omnichannel clearance outlets
Finished‑goods excess isn’t background noise, it’s an early‑warning signal for recession risk and a once‑in‑cycle chance for agile operators.

We are sharing a free Giveaway, directly for your Inbox

We joined hands with the Open Innovation team at 2080 Ventures!!
They are bringing out a Fresh take on Innovation Gaps in Healthcare Industry

It dives into the convergence of AI, biotech, digital health, and public policy, with insights on how corporates, startups, and governments are reshaping healthcare globally.

Highlights include:

⦁ $381 B in 2023 life sciences M&A deals (Pfizer, Merck, Sanofi)

AI-driven drug discovery case: AstraZeneca × Exscientia

Digital health projected to reach $1.6 T by 2033

⦁ Japan’s $3 B Bioeconomy strategy + EU AI Act impact

Charts data, strategy visuals, and quotes included

👇

For more Powerpacked sessions and Insights, Please do remember to follow and share.

🤓 Let us know what do you think of this week's Newsletter!

📲 Hit Reply to share your Views

Unsubscribe | Update your profile | 113 Cherry St #92768, Seattle, WA 98104-2205

Timur & AB - Investor and Operator Duo

Beyond is our Quest to decode the Best Underdog Stories and the worst Startup flukes, we believe, the only way to decode success is "joining the dots backwards". We are building a community of Operators who can contribute to this knowledge base, through their own Experience and unfiltered takes on Global Playbook.

Read more from Timur & AB - Investor and Operator Duo
Unlock your GTM using AI

In This Newsletter, We Will Talk About Here is what you'll gonna learn in the next 10 minutes or less! 150 AI Agents, To Unlock your GTM, Just 2 Clicks away, Exclusive Access How Del Monte’s 139-Year Legacy Got Canned? How did Byju's lost $22 Billion in just 3 years? How a WhatsApp homework chat became a $3.2 billion empire? Here are this Week's Giveaways! 150 AI Agents, To Unlock your GTM, Just 2 Clicks away🥷🏼Exclusive Access before Public Launch How many hours have you wasted researching AI...

Secret Sauce to build Edtech

In This Newsletter, We Will Talk About Here is what you'll gonna learn in the next 10 minutes or less! 150 AI Agents, To Unlock your GTM, Just 2 Clicks away, Exclusive Access How Del Monte’s 139-Year Legacy Got Canned? How did Byju's lost $22 Billion in just 3 years? How a WhatsApp homework chat became a $3.2 billion empire? Here are this Week's Giveaways! 150 AI Agents, To Unlock your GTM, Just 2 Clicks away🥷🏼Exclusive Access before Public Launch How many hours have you wasted researching AI...

Open Innovation Framework in Life Sciences, 2025

Building an Ecosystem for Venture Builders and not Valuations Have you ever wondered, why Pharma Pilots Fail?, and What Real Open Innovation would Look Like in Healthcare? Innovation in life sciences isn’t broken, It’s just incomplete. Corporate R&D is producing moonshots. Startups are pushing boundaries in AI drug discovery and digital therapeutics. Governments are unlocking public health capital. But the system still leaks: We have pilots that never scale Tons of Deeptech startups are lost...